HealWELL AI Inc.

Good day and thank you for standing by. Welcome to the Heal Well AI Fiscal Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 1-1 on your telephone. You will then hear an automated message device and your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that this conference is being recorded. I would like to hand the conference over to your speaker today, Pardeep Senga, Head of Investor Relations. Please go ahead.

Hello, thank you, operator. Joining me on the call today are Dr. Alexander Dorbonovsky, CEO of HealWell, and Scott Nirenbersky, the company's CFO. I trust that everyone has received a copy of our financial results press release that was issued earlier today. Listeners are also encouraged to download a copy of our quarterly financial statements and management discussion and analysis from cdar.com. Please note, portions of today's call, other than historical performance, include statements of forward-looking information within the meaning of applicable securities laws. These statements are made under the safe harbor provisions of those laws. Please refer to today's press release and to our management discussion analysis for further details on the company's risks and forward-looking statements. We provide forward-looking statements solely for the purpose of providing information about management's current expectations and plans relating to the future. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to our forward-looking statements to reflect any change in our expectations or any change in advanced conditions, assumptions, or circumstances on which any such statement is based, except if it's required by law. We use terms such as adjusted EBIT on this conference call, which is a non-IFRS and non-GAP measure. For more information on how we define these terms, please refer to our definitions set out in the management discussion analysis. With that, let me turn the call over to Dr. Alexander Dobronovsky, CEO.

Thank you Pardeep and good day everyone and we hope that you are all keeping safe and healthy and we truly appreciate everyone for joining us today. I'd like to start today's call by providing some introductory commentary about the company. Then Scott, our CFO, will review the financial results for the third quarter, following which I will then provide a much more fulsome and detailed discussion highlighting our vision, strategic plan for the company, the tremendous market opportunity before us, and also some very exciting and material updates on what we have accomplished subsequent to the quarter. Afterwards, we'll have some time for Q&A and concluding remarks. I'm thrilled to convey that Q3 was nothing short of a transformational quarter for the company. First and foremost, we completed the strategic transaction with Well Health Technologies, led by their visionary CEO, Hamed Shabazi. This resulted in the company renaming itself to HealWell AI with a new stock ticker, and launching itself as a healthcare technology and data science company focused on preventative care. Our mission, which we believe is a very important one, is to improve healthcare and save lives through the early identification and detection of disease. HealWell leverages AI to empower patients and doctors to deliver increased access, reduced healthcare costs, and improve patient outcomes. We are extremely excited about the future growth opportunity for the company. And in our view, there's a generational opportunity before us in healthcare data science and artificial intelligence, whereas we believe the landscape couldn't be more ideal to execute on our mission and build a high-growth, leading AI company. I'll expand on this further. In addition, as this is a noteworthy mention, Hewell has entered into a strategic alliance agreement with Well that positions the company for newfound growth and expansion opportunities as an emerging AI-enabled healthcare technology company. Further to this and subsequent to the quarter, we closed a bot deal private placement for gross proceeds of $8 million. With our combined recent fundraising, we are very well capitalized with sufficient cash and no debt on our balance sheet to execute on our organic growth objectives and robust pipeline of acquisition opportunities. Subsequent to the quarter, we have already executed on this pipeline successfully, and I'd like to highlight the announcement we made today to acquire control of Pentavir Research Group, healthcare AI company that, in my view, has built, validated, and deployed into production some of the best artificial intelligence technology in healthcare in the country. This is a very exciting acquisition. The stage is now set with the required building blocks in place to succeed not just from a value perspective in healthcare AI, but also through empowering our provider partners and materially improving patient outcomes. It is an absolute privilege to work with this team and our partners at Well and work on these discerning problems in healthcare. As mentioned, I will provide additional details on the company's direction later on the call, but first I'd like to turn this over to our CFO, Scott, who will review the financial results for the third quarter.